GET DAILY SIGNALSAbbVie (ABBV): Transitioning Beyond Humira in Biopharma
Key Takeaways
- AbbVie (ABBV) is a global, research-based biopharmaceutical company headquartered in North Chicago, Illinois.
- It was created in January 2013 when it was spun off from Abbott Laboratories (ABT).
- The company focuses on immunology, oncology, neuroscience, aesthetics, and eye care, and markets products in more than 175 countries.
- Its best-known brands include Humira, Skyrizi, Rinvoq, and Botox, with Skyrizi and Rinvoq now driving growth as Humira faces biosimilar competition.
- AbbVie generated worldwide net revenues of roughly $56.3 billion in 2024 and employs approximately 55,000 people.
A Quick Overview of AbbVie
AbbVie Inc. stands as one of the world's largest research-based biopharmaceutical companies, recognized for medicines that address chronic and complex conditions including autoimmune diseases, cancer, and neurological disorders. I follow ABBV closely because it pairs a diversified lineup of established blockbuster drugs with a solid pipeline of new treatments. Its profile makes it a key player in the global healthcare sector.
Company Background and Headquarters
AbbVie came into existence on January 1, 2013, when Abbott Laboratories carved out its research-based pharmaceutical operations into a standalone entity. That separation let the higher-growth branded drug business operate independently, while Abbott kept its other medical products, diagnostics, and nutrition lines. The company is based in North Chicago, Illinois, with shares listed on the New York Stock Exchange. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Core Business Areas and Key Products
The company centers its efforts on discovering, developing, manufacturing, and selling innovative medicines, with revenue coming from sales to wholesalers, distributors, pharmacies, hospitals, and government agencies worldwide. Its primary therapeutic areas include immunology treatments for conditions like rheumatoid arthritis and psoriasis (notably Humira, Skyrizi, and Rinvoq), oncology options such as Venclexta and Imbruvica plus newer antibody-drug conjugates, neuroscience medicines including Vraylar and migraine therapies, aesthetics products led by Botox and Juvederm from the Allergan acquisition, and a complementary eye care portfolio.
Revenue Drivers and Market Standing
Humira long served as the main revenue source and ranked among the top-selling drugs globally. Following the loss of U.S. market exclusivity in 2023, biosimilar competition has cut into those sales. Skyrizi and Rinvoq have stepped up as the main growth engines, with Skyrizi bringing in about $11.7 billion and Rinvoq around $6.0 billion in 2024 net revenues, while Humira fell to roughly $9.0 billion. This shift defines much of AbbVie’s current position and strategy going forward.
What Draws Investors to ABBV
Several factors keep ABBV on investors’ radar. The firm has a strong history of launching blockbuster medicines and has shown skill at refreshing its lineup through internal development and acquisitions like the 2020 Allergan deal. Revenue comes from multiple areas, which limits reliance on any one product. Substantial cash flow also supports dividends and buybacks, appealing to those focused on income and longer-term holdings.
Key Risks to Consider
Before investing, it is worth weighing several points. The biggest near-term issue remains the decline in Humira sales due to biosimilars, requiring newer products to fill the gap. Like other drug makers, AbbVie faces potential setbacks in clinical trials, regulatory delays, or loss of patent protection. Pricing pressures from payers can limit revenue, especially outside the U.S., along with broader industry challenges around competition and litigation.
Conclusion
AbbVie operates as a diversified biopharmaceutical leader with a portfolio covering major treatment areas in modern medicine. Its strength lies in moving from reliance on a single blockbuster to a wider multi-franchise platform backed by a pipeline and targeted acquisitions. As it moves through the post-Humira period, the company continues to draw attention from investors interested in the healthcare sector.
Enhancing Research with AI Tools
In my own work, I often rely on Tickeron’s AI Screener to quickly filter large-cap names like ABBV against peers using technicals, fundamentals, and patterns. It helps surface ideas that align with specific strategies without sifting through thousands of results manually. This kind of tool fits well when comparing AbbVie’s transition story to other pharmaceutical holdings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABBV saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for ABBV moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 69 similar instances where the indicator exited the overbought zone. In 35 of the 69 cases the stock moved lower. This puts the odds of a downward move at 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 17 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 20 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ABBV as a result. In 46 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 224 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Seasonality Score of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement